https://orcid.org/0000-0002-2801-416X
References
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(Suppl. 1):S5–S10.
- Committee Opinion No. 504. Screening and diagnosis of gestational diabetes mellitus. Obstet Gynecol. 2011;118:751–753.
- Tutino GE, Tam WH, Yang X, et al. Diabetes and pregnancy: perspectives from Asia. Diabet Med. 2014;31(3):302–318.
- American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27:S88–S90.
- Vambergue A, Valat AS, Dufour P, et al. Pathophysiology of gestational diabetes. J Gynecol Obstet Reprod Biol. 2002;31:4S3–4S10.
- Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468–481.
- Ali HA, Abbas HJ, Naser NA. Preptin and adropin levels as new predictor in women with polycystic ovary syndrome. J Pharm Sci Res. 2018;10:3005–3008.
- Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides. 2013;47:66–70.
- Beigi A, Shirzad N, Nikpour F, et al. Association between serum adropin levels and gestational diabetes mellitus; a case-control study. Gynecol Endocrinol. 2015;31(12):939–941.
- Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013;41:375–380.
- Dąbrowski FA, Jarmużek P, Gondek A, et al. First and third trimester serum concentrations of adropin and copeptin in gestational diabetes mellitus and normal pregnancy. Ginekol Pol. 2016;87(9):629–634.
- Salih HH, Shamil Hussin R, Oubeid WS. Estimation of lepitn, melatonin, and adropin hormones in gestational diabetes mellitus (GDM) in Tikrit city. Indian J Forensic Med Toxicol. 2021;15:2533–2538.
- Sharafeldeen MR, Mohammed RR. Serum adropin and adipose fatty-acid binding protein at 6th week of pregnancy are significant predictors for development of insulin resistance at the 24th week. Int J Adv Res. 2018;6(2):800–809.
- Wells G, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2021. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- Zhang S, Chen Q, Lin X, et al. A review of adropin as the medium of dialogue between energy regulation and immune regulation. Oxid Med Cell Longev. 2020;2020:3947806.
- Ganesh Kumar K, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012;20(7):1394–1402.
- Butler AA, Zhang J, Price CA, et al. Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates. J Biol Chem. 2019;294(25):9706–9719.
- Palizban AA, Yazdani AH, Jahanbani-Ardakani H. Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case-control study from Isfahan, Iran. Arch Physiol Biochem. 2019;1–4.
- Gao S, Ghoshal S, Zhang L, et al. The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem. 2019;294(36):13366–13377.
- Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11 Suppl.):S185–S192.
- Xu L, Ping F, Yin J, et al. Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLOS One. 2013;8(12):e81615.
- Stein S, Stepan H, Kratzsch J, et al. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism. 2010;59(1):33–37.
- Thapa D, Xie B, Manning JR, et al. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol Rep. 2019;7(8):e14043.